855300-09-3

Usage

Uses

Used in Pharmaceutical Industry:
3'-(ethyl(Methyl)carbaMoyl)oxyacetophenone is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to be modified and incorporated into complex molecular structures. Its carbamoyl group can be utilized to form amide linkages, which are common in drug molecules, enhancing the compound's potential as a building block in medicinal chemistry.
Used in Chemical Synthesis:
In the field of chemical synthesis, 3'-(ethyl(Methyl)carbaMoyl)oxyacetophenone is used as a versatile reactant for the preparation of a wide range of organic compounds. Its reactivity allows for the formation of various derivatives, making it a valuable precursor in the synthesis of specialty chemicals, agrochemicals, and other fine chemicals.
Used in Research and Development:
3'-(ethyl(Methyl)carbaMoyl)oxyacetophenone is also used in research and development settings as a probe for studying the reactivity and selectivity of various chemical reactions. Its unique structure can provide insights into reaction mechanisms and help optimize synthetic routes for the production of target molecules.

Upstream product

• 123441-03-2 rivastigmin 
• 42252-34-6 N-ethyl-N-methylcarbamoyl chloride 
• 121-71-1 3-Hydroxyacetophenone 

Downstream Products

• 105601-20-5 rac-rivastigmine 
• 856408-80-5 (R)-N-ethyl-N-methylcarbamic acid-3-(1-hydroxyethyl)phenyl ester 
• 1222073-98-4 rac-1-(N-ethyl-N-methylaminocarbonyloxy)-3-(1-hydroxyethyl)benzene 
• 1257519-35-9 (S)-1-(N-ethyl-N-methylaminocarbonyloxy)-3-(1-hydroxyethyl)benzene 
• 1222073-99-5 (R)-1-(N-ethyl-N-methylaminocarbonyloxy)-3-(1-acetoxyethyl) benzene 
• 1361513-76-9 1-(3-((ethyl(methyl)carbamoyl)oxy)phenyl)vinyl acetate 
• 1176026-49-5 (S)-3-(1-aminoethyl)phenyl ethyl(methyl)carbamate 
• 123441-03-2 rivastigmin 
• 1418318-99-6 C₁₃H₁₉NO₅S 
• 1346602-84-3 3-vinylphenyl N-ethyl-N-methylcarbamate 
• 186507-11-9 (2E)-1-(3-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one 

Relevant academic research and scientific papers

Synthesis method of rivastigmine optical isomerization intermediate and (R)-rivastigmine

The invention provides a synthesis method of a rivastigmine optical isomerization intermediate and (R)-rivastigmine. The method comprises the following steps: carrying out an asymmetric reductive amination reaction on 3-nitromethyl ethyl formate acetophen

SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE

The present invention relates to novel intermediate(s), which are useful for the preparation of Rivastigmine compound of formula (I) and its pharmaceutically acceptable salts. The present invention further relates to the processes for the preparation of such novel intermediate(s) and preparation of Rivastigmine using such novel intermediate(s).

A method for preparing Rivastigmine citrate (by machine translation)

The invention discloses a method for preparing Rivastigmine citrate, said method is to meta-hydroxy acetophenone, methyl ethyl carbamic chloride as the raw material in the isotope energy level transitions, alternately high and low frequency ultrasonic and

Direct asymmetric reductive amination for the synthesis of (S)-rivastigmine

In this article we demonstrate how asymmetric total synthesis of (S)-rivastigmine has been achieved using direct asymmetric reductive amination as the key transformation in four steps. The route started with readily available and cheap m-hydroxyacetophenone, through esterification, asymmetric reductive amination, N-diphenylmethyl deprotection and reductive amination, to provide the final (S)-rivastigmine in 82% overall yield and 96% enantioselectivity. In the asymmetric reductive amination, catalysed by the iridium–phosphoramidite ligand complex and helped by some additives, the readily prepared 3-acetylphenyl ethyl(methyl)carbamate directly reductively coupled with diphenylmethanamine to yield the chiral amine product in 96% ee and 93% yield.

A General Catalytic Method for Highly Cost- and Atom-Efficient Nucleophilic Substitutions

A general formamide-catalyzed protocol for the efficient transformation of alcohols into alkyl chlorides, which is promoted by substoichiometric amounts (down to 34 mol %) of inexpensive trichlorotriazine (TCT), is introduced. This is the first example of a TCT-mediated dihydroxychlorination of an OH-containing substrate (e.g., alcohols and carboxylic acids) in which all three chlorine atoms of TCT are transferred to the starting material. The consequently enhanced atom economy facilitates a significantly improved waste balance (E-factors down to 4), cost efficiency, and scalability (>50 g). Furthermore, the current procedure is distinguished by high levels of functional-group compatibility and stereoselectivity, as only weakly acidic cyanuric acid is released as exclusive byproduct. Finally, a one-pot protocol for the preparation of amines, azides, ethers, and sulfides enabled the synthesis of the drug rivastigmine with twofold SN2 inversion, which demonstrates the high practical value of the presented method.

Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors

A series of novel chalcone-rivastigmine hybrids were designed, synthesized, and tested in vitro for their ability to inhibit human acetylcholinesterase and butyrylcholinesterase. Most of the target compounds showed hBChE selective activity in the micro- a

A kind of carbamate-koncar ketone choline esterase inhibitor and its preparation method and application (by machine translation)

The present invention discloses a kind of carbamate-koncar ketone choline esterase inhibitor and its preparation method and application, belongs to the field of medicinal chemistry. Cholinesterase inhibitors of the invention represented by general formula

Compound and its as L-type calcium channel blocker or/and application of acetylcholine esterase inhibitors

Disclosed in this invention are compounds and the uses as L-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof. The uses of said compounds in the manufactures of a medicament for the treatment of cardiovascular diseases, apoplexy or senile dementia are also disclosed in the present invention.

Synthesis of 3-vinylphenyl ethyl(methyl)carbamate: A potential human metabolite of rivastigmine

Convenient and efficient syntheses of 3-vinylphenyl ethyl (methyl) carbamate, one of potential metabolites from rivastigmine, has been developed. The overall yield is higher than 30% and represents the first direct synthesis of this metabolite from rivast

Chemo-enzymatic synthesis of optically pure rivastigmine intermediate using alcohol dehydrogenase from baker's yeast

An efficient and practical synthesis of (S)-rivastigmine intermediate was developed by employing a chemoenzymatic step toward the synthesis of chiral intermediate N-ethyl-N-methyl-carbamic acid-3-(1S-hydroxy-ethyl)-phenyl ester (2) using crude alcohol deh